|
1
|
Smith T, Dhunnoo G, Mohan I and
Charlton-Menys V: A pilot study showing an association between
platelet hyperactivity and the severity of peripheral arterial
disease. Platelets. 18:245–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Georgescu A, Alexandru N, Andrei E, Dragan
E, Cochior D and Dias S: Effects of transplanted circulating
endothelial progenitor cells and platelet microparticles in
atherosclerosis development. Biol Cell. 108:219–243. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alexandru N, Popov D and Georgescu A:
Platelet dysfunction in vascular pathologies and how can it be
treated. Thromb Res. 129:116–126. 2012. View Article : Google Scholar
|
|
4
|
Sharma G and Berger JS: Platelet activity
and cardiovascular risk in apparently healthy individuals: A review
of the data. J Thromb Thrombolysis. 32:201–208. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Angiolillo DJ: The evolution of
antiplatelet therapy in the treatment of acute coronary syndromes:
From aspirin to the present day. Drugs. 72:2087–2116. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spiel AO, Gilbert JC and Jilma B: von
Willebrand factor in cardiovascular disease: Focus on acute
coronary syndromes. Circulation. 117:1449–1459. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brass LF, Manning DR, Cichowski K and
Abrams CS: Signaling through G proteins in platelets: To the
integrins and beyond. Thromb Haemost. 78:581–589. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Franke TF, Kaplan DR, Cantley LC and Toker
A: Direct regulation of the Akt proto-oncogene product by
phosphati-dylinositol-3,4-bisphosphate. Science. 275:665–668. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guidetti GF, Canobbio I and Torti M:
PI3K/Akt in platelet integrin signaling and implications in
thrombosis. Adv Biol Regul. 59:36–52. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moore SF, van den Bosch MT, Hunter RW,
Sakamoto K, Poole AW and Hers I: Dual regulation of glycogen
synthase kinase 3 (GSK3)αIIb/β3 by protein
kinase C (PKC)α and Akt promotes thrombin-mediated integrin α β
activation and granule secretion in platelets. J Biol Chem.
288:3918–3928. 2013. View Article : Google Scholar
|
|
11
|
Chen X, Zhang Y, Wang Y, Li D, Zhang L,
Wang K, Luo X, Yang Z, Wu Y and Liu J: PDK1 regulates platelet
activation and arterial thrombosis. Blood. 121:3718–3726. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin H, Stojanovic A, Hay N and Du X: The
role of Akt in the signaling pathway of the glycoprotein Ib-IX
induced platelet activation. Blood. 111:658–665. 2008. View Article : Google Scholar
|
|
13
|
Kim S, Mangin P, Dangelmaier C, Lillian R,
Jackson SP, Daniel JL and Kunapuli SP: Role of phosphoinositide
3-kinase beta in glycoprotein VI-mediated Akt activation in
platelets. J Biol Chem. 284:33763–33772. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reséndiz JC, Kroll MH and Lassila R:
Protease-activated receptor-induced Akt activation-regulation and
possible function. J Thromb Haemost. 5:2484–2493. 2007. View Article : Google Scholar
|
|
15
|
Chen J, De S, Damron DS, Chen WS, Hay N
and Byzova TV: Impaired platelet responses to thrombin and collagen
in AKT-1-deficient mice. Blood. 104:1703–1710. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Di Minno MN, Lupoli R, Palmieri NM,
Russolillo A, Buonauro A and Di Minno G: Aspirin resistance,
platelet turnover, and diabetic angiopathy: A 2011 update. Thromb
Res. 129:341–344. 2012. View Article : Google Scholar
|
|
17
|
Uchiyama S: Clopidogrel resistance:
Identifying and overcoming a barrier to effective antiplatelet
treatment. Cardiovasc Ther. 29:e100–e111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Beijing Institute of Pharmaceutical
Industry: Studies of active components of Ligusticum Wallichii
Franch. I. Extraction, isolation and structure identification of
tetramethylpyrazine. Chin Med J. 7:420–421. 1977.In Chinese.
|
|
19
|
Li Z, Li D, Huang J, Zhang W, Ding Y and
Wang S: Preparation of cardiovascular disease-related genes
microarray and its application in exploring ligustrazine-induced
changes in endothelial gene expression. Pol J Pharmacol.
56:427–433. 2004.PubMed/NCBI
|
|
20
|
Zhang F, Ni C, Kong D, Zhang X, Zhu X,
Chen L, Lu Y and Zheng S: Ligustrazine attenuates oxidative
stress-induced activation of hepatic stellate cells by interrupting
platelet-derived growth factor-β receptor-mediated ERK and p38
pathways. Toxicol Appl Pharmacol. 265:51–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li S, Chen H, Wang X, Wu J, Jiang J and
Wang Y: Pharmacokinetic study of a novel stroke therapeutic,
2-[[(1,1-dimethyl-ethyl)oxidoimino]methyl]-3,5,6-trimethylpyrazine,
by a simple HPLC-UV method in rats. Eur J Drug Metab Pharmacokinet.
36:95–101. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu W, Yu X, Luo XP, Yang SH and Zheng D:
Tetramethylpyrazine protects against scopolamine-induced memory
impairments in rats by reversing the cAMP/PKA/CREB pathway. Behav
Brain Res. 253:212–216. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng XR, Zhang L, Hu JJ, Sun L and Du GH:
Neuroprotective effects of tetramethylpyrazine on hydrogen
peroxide-induced apoptosis in PC12 cells. Cell Biol Int.
31:438–443. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han J, Song J, Li X, Zhu M, Guo W, Xing W,
Zhao R, He X, Liu X, Wang S, et al: Ligustrazine suppresses the
growth of HRPC cells through the inhibition of cap-dependent
translation via both the mTOR and the MEK/ERK pathways. Anticancer
Agents Med Chem. 15:764–772. 2015. View Article : Google Scholar
|
|
25
|
Wang GJ: Changes of nail fold
microcirculation in patients with acute cerebral thrombosis treated
with ligustrazine. Chin J Neurol Psychiatry. 17:121–124. 1984.In
Chinese.
|
|
26
|
Sheu JR, Kan YC, Hung WC, Ko WC and Yen
MH: Mechanisms involved in the antiplatelet activity of
tetramethylpyrazine in human platelets. Thromb Res. 88:259–270.
1997. View Article : Google Scholar
|
|
27
|
Lin CI, Wu SL, Tao PL, Chen HM and Wei J:
The role of cyclic AMP and phosphodiesterase activity in the
mechanism of action of tetramethylpyrazine on human and dog cardiac
and dog coronary arterial tissues. J Pharm Pharmacol. 45:963–966.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu SF, Cai YN, Evans TW, McCormack DG,
Barer GR and Barnes PJ: Ligustrazine is a vasodilator of human
pulmonary and bronchial arteries. Eur J Pharmacol. 191:345–350.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng W, Hucks D, Priest RM, Kan YM and
Ward JP: Ligustrazine-induced endothelium-dependent relaxation in
pulmonary arteries via an NO-mediated and exogenous
L-arginine-dependent mechanism. Br J Pharmacol. 119:1063–1071.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alshbool FZ, Karim ZA, Vemana HP, Conlon
C, Lin OA and Khasawneh FT: The regulator of G-protein signaling 18
regulates platelet aggregation, hemostasis and thrombosis. Biochem
Biophys Res Commun. 462:378–382. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Su XL, Su W, Wang Y, Wang YH, Ming X and
Kong Y: The pyrrolidinoindoline alkaloid Psm2 inhibits platelet
aggregation and thrombus formation by affecting PI3K/Akt signaling.
Acta Pharmacol Sin. 37:1208–1217. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sakariassen KS, Alberts P, Fontana P, Mann
J, Bounameaux H and Sorensen AS: Effect of pharmaceutical
interventions targeting thromboxane receptors and thromboxane
synthase in cardiovascular and renal diseases. Future Cardiol.
5:479–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fontana P, Zufferey A, Daali Y and Reny
JL: Antiplatelet therapy: Targeting the TxA2 pathway. J
Cardiovasc Transl Res. 7:29–38. 2014. View Article : Google Scholar
|
|
34
|
Varga-Szabo D, Braun A and Nieswandt B:
Calcium signaling in platelets. J Thromb Haemost. 7:1057–1066.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Berridge MJ, Bootman MD and Roderick HL:
Calcium signalling: Dynamics, homeostasis and remodelling. Nat Rev
Mol Cell Biol. 4:517–529. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Heraud JM, Racaud-Sultan C, Gironcel D,
Albigès-Rizo C, Giacomini T, Roques S, Martel V, Breton-Douillon M,
Perret B and Chap H: Lipid products of phosphoinositide 3-kinase
and phosphatidylinositol 4′,5′-bisphosphate are both required for
ADP-dependent platelet spreading. J Biol Chem. 273:17817–17823.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Canobbio I, Stefanini L, Cipolla L,
Ciraolo E, Gruppi C, Balduini C, Hirsch E and Torti M: Genetic
evidence for a predominant role of PI3Kbeta catalytic activity in
ITAM- and integrin-mediated signaling in platelets. Blood.
114:2193–2196. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Woulfe DS: Akt signaling in platelets and
thrombosis. Expert Rev Hematol. 3:81–91. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
O’Brien KA, Stojanovic-Terpo A, Hay N and
Du X: An important role for Akt3 in platelet activation and
thrombosis. Blood. 118:4215–4223. 2011. View Article : Google Scholar :
|
|
40
|
Stojanovic A, Marjanovic JA, Brovkovych
VM, Peng X, Hay N, Skidgel RA and Du X: A phosphoinositide
3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating
platelet secretion and aggregation. J Biol Chem. 281:16333–16339.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Laurent PA, Severin S, Gratacap MP and
Payrastre B: Class I PI 3-kinases signaling in platelet activation
and thrombosis: PDK1/Akt/GSK3 axis and impact of PTEN and SHIP1.
Adv Biol Regul. 54:162–174. 2014. View Article : Google Scholar
|
|
42
|
Meuillet EJ: Novel inhibitors of AKT:
Assessment of a different approach targeting the pleckstrin
homology domain. Curr Med Chem. 18:2727–2742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ishibashi O, Akagi I, Ogawa Y and Inui T:
MiR-141-3p is upregulated in esophageal squamous cell carcinoma and
targets pleckstrin homology domain leucine-rich repeat protein
phosphatase-2, a negative regulator of the PI3K/AKT pathway.
Biochem Biophys Res Commun. 501:507–513. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Razmara M, Heldin CH and Lennartsson J:
Platelet-derived growth factor-induced Akt phosphorylation requires
mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphory-lation
depends on mTOR/Raptor and phospholipase D. Cell Commun Signal.
11:32013. View Article : Google Scholar
|
